Trial Profile
A Dose-Escalation Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of CEP-9722 (a PARP 1 and PARP 2 Inhibitor) in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell Lymphoma.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs CEP 9722 (Primary) ; Cisplatin; Gemcitabine
- Indications Mantle-cell lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Cephalon
- 01 Jan 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 10 Nov 2011 Official Title amended as reported by ClinicalTrials.gov.
- 10 Nov 2011 Actual initiation date (May 2011) added as reported by ClinicalTrials.gov.